These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9677534)

  • 21. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
    Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
    Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
    Ramsey S; Aitchison M; Graham J; McMillan DC
    BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
    In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
    Royal RE; Steinberg SM; Krouse RS; Heywood G; White DE; Hwu P; Marincola FM; Parkinson DR; Schwartzentruber DJ; Topalian SL; Yang JC; Rosenberg SA
    Cancer J Sci Am; 1996; 2(2):91-8. PubMed ID: 9166506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
    Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
    J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-angiogenic activity of melatonin in advanced cancer patients.
    Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
    Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.
    Vis AN; van der Gaast A; van Rhijn BW; Catsburg TK; Schmidt C; Mickisch GH
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):342-5. PubMed ID: 11914915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.